Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy
Status:
Completed
Trial end date:
2018-01-08
Target enrollment:
Participant gender:
Summary
After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade
osteosarcoma is dismal and unchanged over the last decades.Thus, the investigators explored
apatinib activity in patients with relapsed and unresectable osteosarcoma after the failure
of first-line or second-line chemotherapy. Patients >16 years, progressing after standard
treatment, were eligible to receive 500 mg or 750 mg of apatinib once daily until progression
or unacceptable toxicity. The primary end point was progression-free survival (PFS) at 4
months and objective response rate (ORR). Secondary objectives were PFS, overall survival
(OS), clinical benefit rate (CBR), defined as no progression at 6 months and safety.